Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab

2019-06-17 03:02:41 | BioPortfolio

Published on BioPortfolio: 2019-06-17T03:02:41-0400

Clinical Trials [2764 Associated Clinical Trials listed on BioPortfolio]

Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

Single center Phase 1 dose escalation trial of the combination of standard-of-care blinatumomab plus Haplo-Mismatched Cellular Therapy (HMCT). HMCT refers to the infusion of donor peripher...

SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)

The goal of this clinical research study is to learn if giving donor lymphocyte cells and SGI-110 will help control AML and MDS. The safety of this treatment will also be studied.

Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab

The trial proposed here attempts to reduce induction chemotherapy to phase I of standard induction in patients with B-precursor ALL. Induction phase II will be replaced by blinatumomab. ...

Donor Lymphocyte Infusion After Alternative Donor Transplantation

The purpose of this study is to determine the ability of a donor lymphocyte infusion (DLI) given with methotrexate to hasten immune recovery without causing severe graft-versus-host diseas...

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.

PubMed Articles [19157 Associated PubMed Articles listed on BioPortfolio]

Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.

Adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with conventional chemotherapy have dismal outcomes. Novel immunotherapies targeting CD19, including the bi...

Clearance of hematological malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions.

Well-established donor lymphocyte infusion (DLI) and novel cytokine-induced killer (CIK) cell therapy for the treatment of relapsing hematological malignancies after allogeneic hematopoietic stem cell...

G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients.

Donor lymphocyte infusion (DLI) is an effective method to establish full donor chimerism or to prevent and treat relapse after allogeneic haematopoietic cell transplantation (allo-HCT). Usually, DLIs ...

CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.

T cell immunotherapies are promising options in leukemia, among which the CD19/CD3-bispecific T cell engager antibody blinatumomab (MT103) has shown high response rates at very low doses in patients w...

CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach To Immunotherapy Following Haploidentical Transplantation for Advanced Leukemia.

CTLA4Ig attenuates T cell activation by costimulation blockade, but natural killer (NK) cells are not only resistant to CTLA4Ig, they might demonstrate better anti-leukemia effect in presence of CTLA4...

Medical and Biotech [MESH] Definitions

Lymphocyte progenitor cells that are restricted in their differentiation potential to the B lymphocyte lineage. The pro-B cell stage of B lymphocyte development precedes the pre-B cell stage.

The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.

Lymphocyte progenitor cells that are restricted in their differentiation potential to the T lymphocyte lineage.

The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement.

The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in PLASMAPHERESIS and types of CYTAPHERESIS; (PLATELETPHERESIS and LEUKAPHERESIS) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor.

More From BioPortfolio on "Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab"

Quick Search


Searches Linking to this Trial